Psyched: Cybin Debuts On NYSE, Nonprofits In Psychedelics Space Reach New Milestones, Filament Receives Psilocybin Patent
Cybin Debuts On The NYSE
Last week, Cybin (NYSE: CYBN) began listing its stock on the New York Stock Exchange.
Cukes, Cannabis, Peppers And Tomatoes: Village Farms Has The Full Salad, Cantor Fitzgerald Calls Co’s Q2 Earnings ‘Neutral But Constructive’
Village Farms International (NASDAQ: VFF) (TSX: VFF) reported second-quarter financial
J&J’s Janssen Denied Data Protection Rights For Ketamine Analog Spravato In Canada, Court Rules ‘Not An Innovative Drug’
The Federal Court of Appeals in Canada ratified a Ministry of Health decision to refuse to provide Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson (NYSE: JNJ), data protection for Spravato, a ketamine analog approved for depression.
Canopy Growth Cannabis Co. Falls Short On Q1 Sales, Cantor Maintains Neutral Rating
On Friday, Canopy Growth (NASDAQ: CGC) (TSX: WEED) released its first-quarter financial results for the fiscal year 2022, ending on June 30, 2021.
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha.
In just a couple of years, psychedelics took the world of investing by storm.
Field Trip Health Debuts On Nasdaq With Average Performance, Looks To Expand Footprint Of Psychedelics Clinics
Field Trip Health (TSX: FTRP) (NASDAQ: FTRP) made its Nasdaq debut on Thursday, becoming the fifth company in the psychedelics space to receive a welcome by Wall Street this year.
UK Psychedelics Co. Awakn Life Sciences Begins Listing On OTC Markets
Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF), a biotech company with clinical operations in the psychedelics space looking at the UK mental health markets, began trading on Monday in the U.S. OTC markets under the symbol “AWKNF.”
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To “Psychedelics Renaissance”
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector.
Psyched: Investment Banks Bullish On Atai Life Sciences, Wesana’s $17M Purchase Of PsyTech, Creso Pharma Acquires Halucenex
A number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ: ATAI) last week.